Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Tagoor Lab Vildagliptin

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Xiliarx

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 515Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 9Equa/EquMet

    02 6Galvus

    03 4Galvus Group

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 391

    2019 Revenue in Millions : 75

    Growth (%) : 421

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 391

    2019 Revenue in Millions : 75

    Growth (%) : 421

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Galvus Group

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Galvus Group

    Switzerland
    arrow
    BioFlorida Conference
    Not Confirmed

    Novartis

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 1,199

    2019 Revenue in Millions : 1,297

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 322

    2020 Revenue in Millions : 391

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 322

    2020 Revenue in Millions : 391

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Galvus Group

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Galvus Group

    Switzerland
    arrow
    BioFlorida Conference
    Not Confirmed

    Novartis

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 1,092

    2020 Revenue in Millions : 1,199

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Galvus Group

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Galvus Group

    Switzerland
    arrow
    BioFlorida Conference
    Not Confirmed

    Novartis

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 859

    2021 Revenue in Millions : 1,092

    Growth (%) : -21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 272

    2021 Revenue in Millions : 322

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 272

    2021 Revenue in Millions : 322

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2023 Revenue in Millions : 210

    2022 Revenue in Millions : 251

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF